- Type / Class
- Equity / COMMON STOCK
- Shares outstanding
- 282,656,386
- Total 13F shares
- 214,909,404
- Share change
- -3,190,957
- Total reported value
- $468,512,239
- Put/Call ratio
- 11%
- Price per share
- $2.18
- Number of holders
- 138
- Value change
- -$3,508,720
- Number of buys
- 54
- Number of sells
- 59
Quarterly Holders Quick Answers
What is CUSIP 29479A108?
CUSIP 29479A108 identifies ERAS - Erasca, Inc. - COMMON STOCK in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 29479A108:
Top shareholders of ERAS - Erasca, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Logos Global Management LP |
13D/G
13F
|
Company |
4.8%
|
13,600,000
|
$29,648,000 | -$3,270,000 | 30 Sep 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
8%
|
22,729,436
|
$28,866,384 | — | 30 Jun 2025 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
7.2%
|
20,332,161
|
$25,822,000 | — | 30 Jun 2025 | |
| VR Adviser, LLC |
13F
|
Company |
6.3%
|
17,857,083
|
$22,678,495 | — | 30 Jun 2025 | |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
— |
5.3%
|
15,038,753
|
$21,355,029 | -$10,702,679 | 30 Jun 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13D/G
13F
|
Company |
5.1%
|
14,502,004
|
$20,592,846 | +$3,105,540 | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
|
Company |
5.4%
|
15,166,198
|
$19,261,072 | — | 30 Jun 2025 | |
| ARCH Venture Partners X, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
11,055,554
|
$17,572,804 | — | 20 Jul 2021 | |
| Bihua Chen |
3/4/5
|
Director |
—
mixed-class rows
|
10,873,246
mixed-class rows
|
$17,187,655 | — | 22 Jun 2023 | |
| NOVARTIS PHARMA AG |
13D/G
|
— |
4.4%
|
12,307,692
|
$17,107,692 | $0 | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.5%
|
12,695,597
|
$16,123,408 | — | 30 Jun 2025 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
4.2%
|
11,907,182
|
$15,122,121 | — | 30 Jun 2025 | |
| ARCH Venture Management, LLC |
13F
|
Company |
3.9%
|
11,055,554
|
$14,095,831 | — | 30 Jun 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
3.1%
|
8,757,249
|
$11,121,706 | — | 30 Jun 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
2.4%
|
6,756,756
|
$8,581,080 | — | 30 Jun 2025 | |
| 5AM Venture Management, LLC |
13F
|
Company |
1.9%
|
5,405,404
|
$6,864,863 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.7%
|
4,835,642
|
$6,142,749 | — | 30 Jun 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
1.4%
|
4,085,787
|
$5,188,949 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.4%
|
4,002,110
|
$5,082,680 | — | 30 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.3%
|
3,797,987
|
$4,823,443 | — | 30 Jun 2025 | |
| a16z Capital Management, L.L.C. |
13F
|
Company |
1%
|
2,862,500
|
$3,635,375 | — | 30 Jun 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.91%
|
2,569,591
|
$3,263,381 | — | 30 Jun 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.76%
|
2,162,162
|
$2,745,946 | — | 30 Jun 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.73%
|
2,074,425
|
$2,634,519 | — | 30 Jun 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.73%
|
2,074,390
|
$2,634,475 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.64%
|
1,819,849
|
$2,311,208 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.6%
|
1,696,593
|
$2,154,673 | — | 30 Jun 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.6%
|
1,693,423
|
$2,151,401 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.56%
|
1,571,325
|
$1,995,583 | — | 30 Jun 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.53%
|
1,502,915
|
$1,908,702 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.5%
|
1,411,022
|
$1,791,998 | — | 30 Jun 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.49%
|
1,372,569
|
$1,743,162 | — | 30 Jun 2025 | |
| Sio Capital Management, LLC |
13F
|
Company |
0.48%
|
1,369,748
|
$1,739,580 | — | 30 Jun 2025 | |
| PFM Health Sciences, LP |
13F
|
Company |
0.38%
|
1,072,224
|
$1,361,724 | — | 30 Jun 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.31%
|
885,651
|
$1,124,777 | — | 30 Jun 2025 | |
| Jain Global LLC |
13F
|
Company |
0.27%
|
774,340
|
$983,412 | — | 30 Jun 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.26%
|
742,500
|
$942,975 | — | 30 Jun 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.25%
|
708,060
|
$899,236 | — | 30 Jun 2025 | |
| Octagon Capital Advisors LP |
13F
|
Company |
0.25%
|
700,000
|
$889,000 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.22%
|
609,343
|
$773,866 | — | 30 Jun 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.21%
|
605,390
|
$769,000 | — | 30 Jun 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.2%
|
555,194
|
$705,096 | — | 30 Jun 2025 | |
| Atom Investors LP |
13F
|
Company |
0.19%
|
549,959
|
$698,448 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.18%
|
495,647
|
$629,472 | — | 30 Jun 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.16%
|
450,056
|
$571,571 | — | 30 Jun 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.15%
|
427,603
|
$543,056 | — | 30 Jun 2025 | |
| Wei Lin |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
875,812
mixed-class rows
|
$501,983 | — | 01 Feb 2023 | |
| FMR LLC |
13F
|
Company |
0.13%
|
376,976
|
$478,760 | — | 30 Jun 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.12%
|
350,000
|
$444,500 | — | 30 Jun 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.11%
|
323,480
|
$410,819 | — | 30 Jun 2025 |
Institutional Holders of Erasca, Inc. - COMMON STOCK (ERAS) as of Q3 2025
As of 30 Sep 2025,
Erasca, Inc. - COMMON STOCK (ERAS) was held by
138 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
214,909,404 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., T. Rowe Price Investment Management, Inc., VR ADVISER, LLC, Logos Global Management LP, BlackRock, Inc., SUVRETTA CAPITAL MANAGEMENT, LLC, Paradigm Biocapital Advisors LP, VANGUARD GROUP INC, ARCH Venture Management, LLC, and Vivo Capital, LLC.
This page lists
138
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
141
Q3 2025 holders
138
Holder diff
-3
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.